- Approval Id
- 15a917569bc6a0c0
- Drug Approval Emc Name
- Velphoro 125 mg oral powder in sachet
- Drug Name
- Velphoro 125 mg oral powder in sachet
- Company Name
- Vifor Fresenius Medical Care Renal Pharma UK Ltd
- Company Address
- Point, 29 Market Street, Maidenhead, SL6 8AA, UK
- Company Telephone
- +44 (0)1276 853 600
- Company Medical Info Direct Line
- +44 (0)1276 853 633
- Company Medical Info Email
- medicalinfo_UK@viforpharma.com
- Atc Code
- V03AE05
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Vifor Fresenius Medical Care Renal Pharma France
100–101 Terrasse Boieldieu
Tour Franklin La Défense 8
92042 Paris la Défense Cedex
France
- Authorisation Number
- PLGB 50784/0007
- Authorisation Date
- 01/01/2021
- Instruction Authorisation Holder
- Vifor Fresenius Medical Care Renal Pharma France
100–101 Terrasse Boieldieu
Tour Franklin La Défense 8
92042 Paris la Défense Cedex
France
- Instruction Authorisation Number
- PLGB 50784/0007
- Instruction Authorisation Date
- 01/01/2021
- Instruction Composition
- Each sachet contains sucroferric oxyhydroxide corresponding to 125 mg iron.
The sucroferric oxyhydroxide contained in one sachet of oral powder is comprised of polynuclear iron (III)-oxyhydroxide (containing 125 mg iron), 187 mg sucrose and 175 mg starches (potato starch and pregelatinised maize starch).
For the full list of excipients, see section 6.1.
- Instruction Dosage Form
- Oral powder in sachet.
The oral powder is red-brown.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
Velphoro is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD).
Velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with CKD stages 4-5 (defined by a glomerular filtration rate <30 mL/min/1.73 m²) or with CKD on dialysis.
Velphoro should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease.4.2 Posology and method of administration
\*\*Posology\*\*
\*\*\*Starting dose, dose titration and maintenance for paediatric patients 2 to <12 years of age\*\*\*
The recommended starting doses for paediatric patients in different age groups are described in Table 1.
\*\*Table 1 Recommended starting doses and dose titrations for paediatric patients 2 to <12 years of age\*\*
| | | | |
| --- | --- | --- | --- |
| \*\*Patient age (years)\*\* | \*\*Daily starting dose\*\* | \*\*Dose increases or decreases\*\* | \*\*Maximum recommended daily dose\*\* |
| ≥2 to <6 | 500 mg | 125 or 250 mg | 1,250 mg |
| ≥6 to <9 | 750 mg | 125, 250 or 375 mg | 2,500 mg |
| ≥9 to <12 | 1,000 mg | 250 or 500 mg | 3,000 mg |
Serum phosphorus levels must be monitored and the dose of sucroferric oxyhydroxide up or down titrated once per two weeks by adjusting the daily dose as indicated in Table 1 until an acceptable serum phosphorus level is reached, with regular monitoring afterwards.
For patients 6 to <12 years of age Velphoro chewable tablets may be prescribed instead of or in combination with Velphoro oral powder in case the daily dose is 1,000 mg iron (2 chewable tablets) or more.
If one or more doses are missed, the normal dose of the medicinal product should be resumed with the next meal.
\*\*\*Additional formulation and strength available\*\*\*
Velphoro is also available as chewable tablets (500 mg iron) for use in adult and paediatric patients 6 years of age and older. The choice of the formulation depends on patient's age, preference, characteristics and compliance. When transitioning between formulations, the same recommended dose should be used. Velphoro oral powder was not studied in adults. For patients 2 to <6 years of age oral powder should be administered as chewable tablet formulation is not appropriate for this age group.
\*\*\*Paediatric population <2 years of age\*\*\*
The safety and efficacy of Velphoro in children below the age of 2 years has not been established. No data are available.
\*\*\*Renal impairment\*\*\*
Velphoro is indicated for the control of serum phosphorus levels in adult CKD patients on HD or PD. There is no clinical data available in patients with earlier stages of renal impairment.
\*\*\*Hepatic impairment\*\*\*
Patients with severe hepatic impairment were excluded from participating in clinical studies with sucroferric oxyhydroxide. However, no evidence of hepatic impairment or significant alteration of hepatic enzymes were observed in the clinical studies with sucroferric oxyhydroxide. See further information in section 4.4.
\*\*Method of administration\*\*
Oral use.
In order to maximise the adsorption of dietary phosphate, the total daily dose (total number of sachets) should be divided across the main meals of the day, i.e. meals with the highest phosphate content. When total number of sachets cannot be equally divided by the number of main meals, rest of the dose should be taken with one or two main meals. The optimal way to give the total daily dose of Velphoro to individual patients should be decided based on their feeding regimens.
Before administration, Velphoro oral powder should be mixed with a small amount of soft food (such as apple sauce) or with non-carbonated beverage or water and taken with meals. Each sachet of oral powder requires minimum 5 mL of liquid for suspension, e.g. 2 sachets shall be suspended in minimum 10 mL. The amount of liquid could be increased if total daily fluid intake remains in line with dietary instructions for individual patient.
Patients should take Velphoro oral powder within 30 minutes after being suspended. Velphoro oral powder should not be heated (e.g. in a microwave) or added to heated food or liquids. The mixture should be stirred vigorously as the powder will not dissolve completely and remain in suspension with a red-brown colour. If necessary, the suspension should be resuspended right before administration.
The prescribed dose of Velphoro oral powder suspended in water as described above, may be administered via an enteral feeding tube >6 FR (French catheter scale). Follow the manufacturer's instructions for the feeding tube to administer the medicinal product. To ensure adequate dosing, after administration of the oral suspension, the enteral feeding tube must be flushed with water. See section 6.6 for further details.4.3 Contraindications
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Haemochromatosis and any other iron accumulation disorders.4.4 Special warnings and precautions for use
\*\*Peritonitis, gastric and hepatic disorders and gastrointestinal surgery\*\*
Patients with a recent history of peritonitis (within the last 3 months), significant gastric or hepatic disorders and patients with major gastrointestinal surgery have not been included in clinical studies with Velphoro. Velphoro treatment should only be used in these patients following careful assessment of benefit/risk.
\*\*Discoloured stool\*\*
Sucroferric oxyhydroxide can cause discoloured (black) stool. Discoloured (black) stool may visually mask gastrointestinal bleeding (see section 4.5).
\*\*Information about sucrose and starches (carbohydrates)\*\*
Velphoro contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product.
It may be harmful to the teeth.
Velphoro contains potato starch and pregelatinised maize starch. Patients with diabetes should take notice that one sachet of Velphoro oral powder is equivalent to approximately 0.7 g of carbohydrates (equivalent to 0.056 bread units).4.5 Interaction with other medicinal products and other forms of interaction
Velphoro is almost not absorbed from the gastrointestinal tract. Although the potential for interactions with medicinal products seems low, for concomitant treatment with medicinal products with a narrow therapeutic window, the clinical effect and adverse events should be monitored, on initiation or dose-adjustment of either Velphoro or the concomitant medicinal product, or the physician should consider measuring blood levels. When administering any medicinal product that is already known to interact with iron (like alendronate and doxycycline) or has the potential to interact with sucroferric oxyhydroxide based only on \*in vitro\* studies like levothyroxine, the medicinal product should be administered at least one hour before or two hours after Velphoro.
\*In vitro\* studies with the following active substances did not show any relevant interaction: acetylsalicylic acid, cephalexin, cinacalcet, ciprofloxacin, clopidogrel, enalapril, hydrochlorothiazide, metformin, metoprolol, nifedipine, pioglitazone and quinidine.
Interaction studies have only been performed in healthy volunteers. They have been conducted in healthy human male and female subjects with losartan, furosemide, digoxin, warfarin, and omeprazole. Concomitant administration of Velphoro did not affect the bioavailability of these medicinal products as measured by the area under the curve (AUC).
Data from clinical studies have shown that sucroferric oxyhydroxide does not affect the lipid lowering effects of HMG-CoA reductase inhibitors (e.g., atorvastatin and simvastatin). In addition, post-hoc analyses from clinical studies demonstrated no impact of Velphoro on iPTH lowering effect of oral Vitamin D analogues. Vitamin D and 1,25-dihydroxy Vitamin D levels remained unchanged.
Velphoro does not affect guaiac based (Haemoccult) or immunological based (iColo Rectal and Hexagon Obti) faecal occult blood tests.4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
There are no available clinical data from the use of sucroferric oxyhydroxide on exposed human pregnancies.
Reproductive and developmental toxicity studies in animals revealed no risk with respect to pregnancy, embryonic/foetal development, parturition or postnatal development (see section 5.3). Sucroferric oxyhydroxide should only be used by pregnant women if clearly needed following careful assessment of benefit/risk.
\*\*Breast-feeding\*\*
There are no available clinical data from the use of Velphoro in breast-feeding women. Since absorption of iron from this medicinal product is minimal (see section 5.2), excretion of iron from sucroferric oxyhydroxide in breast milk is unlikely. A decision on whether to continue breast-feeding or to continue therapy with sucroferric oxyhydroxide should be made taking into account the benefit of breast-feeding to the child and the benefit of Velphoro therapy to the mother.
\*\*Fertility\*\*
There are no data on the effect of Velphoro on fertility in humans. In animal studies, there were no adverse effects on mating performance, fertility, and litter parameters following treatment with sucroferric oxyhydroxide (see section 5.3).4.7 Effects on ability to drive and use machines
Velphoro has no or negligible influence on the ability to drive and use machines.4.8 Undesirable effects
\*\*Summary of the safety profile\*\*
The current safety profile of Velphoro is based on a total of 778 patients on haemodialysis and 57 patients on peritoneal dialysis, who received sucroferric oxyhydroxide treatment of up to 55 weeks.
In these clinical trials, approximately 43% of the patients experienced at least one adverse reaction during Velphoro treatment, and 0.36% of the adverse reactions were reported as serious. The majority of the adverse reactions reported from trials were gastrointestinal disorders, with the most frequently reported adverse reactions being diarrhoea and discoloured faeces (very common). The vast majority of these gastrointestinal disorders occurred early during treatment and abated with time with continued dosing. No dose-dependent trends were observed in the adverse reaction profile of Velphoro.
\*\*Tabulated list of adverse reactions\*\*
Adverse reactions reported from the use of Velphoro at doses from 250 mg iron/day to 3,000 mg iron/day in these patients (n=835) are listed in Table 2.
The reporting rate is classified as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100).
\*\*Table 2 Adverse reactions detected in clinical trials\*\*
| | | | |
| --- | --- | --- | --- |
| \*\*System organ class\*\* | \*\*Very common\*\* | \*\*Common\*\* | \*\*Uncommon\*\* |
| Metabolism and nutrition disorders | | | Hypercalcaemia Hypocalcaemia |
| Nervous system disorders | | | Headache |
| Respiratory, thoracic and mediastinal disorders | | | Dyspnoea |
| Gastrointestinal disorders | Diarrhoea\\* Faeces discoloured | Nausea Constipation Vomiting Dyspepsia Abdominal pain Flatulence Tooth discolouration | Abdominal distension Gastritis Abdominal discomfort Dysphagia Gastro-oesophageal reflux disease (GORD) Tongue discolouration |
| Skin and subcutaneous tissue disorders | | | Pruritus Rash |
| General disorders and administration site conditions | | Product taste abnormal | Fatigue |
\*\*Description of selected adverse reactions\*\*
\*\*\*\\*Diarrhoea\*\*\*
Diarrhoea occurred in 11.6% of patients in clinical trials. In the 55 weeks long term studies, the majority of these diarrhoea adverse reactions were transient, occurred early during treatment initiation and led to treatment discontinuation in 3.1% of the patients.
\*\*Paediatric population\*\*
In general, the safety profile of Velphoro in paediatric (2 to <18 years of age) and adult patients was comparable. The adverse reactions most frequently reported were gastrointestinal disorders including diarrhoea (very common, 16.7%), vomiting (common, 6.1%), gastritis (common, 3.0%) and discoloured faeces (common, 3.0%).
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store4.9 Overdose
Any instances of overdose of Velphoro (e.g. hypophosphataemia) should be treated by standard clinical practice.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: All other therapeutic products; drugs for treatment of hyperkalaemia and hyperphosphataemia; ATC code: V03AE05
\*\*Mechanism of action\*\*
Velphoro contains sucroferric oxyhydroxide which is comprised of polynuclear iron(III)-oxyhydroxide (pn-FeOOH), sucrose and starches. Phosphate binding takes place by ligand exchange between hydroxyl groups and/or water and the phosphate ions throughout the physiological pH range of the gastrointestinal tract.
Serum phosphorus levels are reduced as a consequence of the reduced dietary phosphate absorption.
\*\*Clinical efficacy\*\*
One phase 3 clinical study has been performed in patients with CKD on dialysis to investigate the efficacy and safety of Velphoro in this population. This study was an open-label, randomised, active-controlled (sevelamer carbonate), parallel group study for up to 55 weeks. Adult patients with hyperphosphataemia (serum phosphorus levels ≥1.94 mmol/L) were treated with sucroferric oxyhydroxide at a starting dose of 1,000 mg iron/day followed by an 8-week dose titration period. Non-inferiority to sevelamer carbonate was determined at week 12. Subjects were continued on their study medication from week 12 to week 55. From week 12 to 24, dose titrations were allowed for both tolerability and efficacy reasons. Treatment of patient sub-populations from week 24 to week 27 with maintenance dose of sucroferric oxyhydroxide (1,000 to 3,000 mg iron/day) or low dose (250 mg iron/day) of sucroferric oxyhydroxide demonstrated superiority of the maintenance dose.
In Study-05A, 1,055 patients on haemodialysis (N=968) or peritoneal dialysis (N=87) with serum phosphorus ≥1.94 mmol/L following a 2 – 4-week phosphate binder washout period, were randomised and treated with either sucroferric oxyhydroxide, at a starting dose of 1,000 mg iron/day (N=707), or active-control (sevelamer carbonate, N=348) for 24 weeks. At the end of week 24, 93 patients on haemodialysis whose serum phosphorus levels were controlled (<1.78 mmol/L) with sucroferric oxyhydroxide in the first part of the study, were re-randomised to continue treatment with either their week 24 maintenance dose (N=44 or a non-effective low dose control 250 mg iron/day, N=49) of sucroferric oxyhydroxide for a further 3 weeks.
Following completion of Study-05A, 658 patients (597 on haemodialysis and 61 on peritoneal dialysis) were treated in the 28-week extension study (Study-05B) with either sucroferric oxyhydroxide (N=391) or sevelamer carbonate (N=267) according to their original randomization.
Mean serum phosphorus levels were 2.5 mmol/L at baseline and 1.8 mmol/L at week 12 for sucroferric oxyhydroxide (reduction by 0.7 mmol/L). Corresponding levels for sevelamer carbonate at baseline were 2.4 mmol/L and 1.7 mmol/L at week 12 (reduction by 0.7 mmol/L), respectively.
The serum phosphorus reduction was maintained over 55 weeks. Serum phosphorus levels and calcium-phosphorus product levels were reduced as a consequence of the reduced dietary phosphate absorption.
The response rates, defined as the proportion of subjects achieving serum phosphorus levels within the Kidney Disease Outcomes Quality Initiative (KDOQI) recommended range were 45.3% and 59.1% at week 12 and 51.9% and 55.2% at week 52, for sucroferric oxyhydroxide and sevelamer carbonate, respectively.
The mean daily dose of Velphoro over 55 weeks of treatment was 1,650 mg iron and the mean daily dose of sevelamer carbonate was 6,960 mg.
\*\*Post-authorisation data\*\*
A prospective, non-interventional, post-authorisation safety study (VERIFIE) has been conducted, evaluating the short- and long-term (up to 36 months) safety and effectiveness of Velphoro in adult patients on haemodialysis (N=1,198) or peritoneal dialysis (N=160), who were followed in routine clinical practice for 12 to 36 months (safety analysis set, N=1,365). During the study, 45% (N=618) of these patients were concomitantly treated with phosphate binder(s) other than Velphoro.
In the safety analysis set, the most common ADRs were diarrhoea and discoloured faeces, reported by 14% (N=194) and 9% (N=128) of patients, respectively. The incidence of diarrhoea was highest in the first week and decreased with duration of use. Diarrhoea was of mild to moderate intensity in most patients and resolved in the majority of patients within 2 weeks. Discoloured (black) faeces is expected for an oral iron-based compound, and may visually mask gastrointestinal bleeding. For 4 of the 40 documented concomitant gastrointestinal bleeding events, Velphoro-related stool discolouration was reported as causing an insignificant delay in diagnosis of gastrointestinal bleeding, without affecting patient health. In the remaining cases, no delay in diagnosis of gastrointestinal bleeding has been reported.
The results from this study showed that the effectiveness of Velphoro in a real-life setting (including concomitant use of other phosphate binders in 45% of patients), was in line with that observed in the phase 3 clinical study.
\*\*Paediatric population\*\*
An open label clinical study investigated the efficacy and safety of Velphoro in paediatric patients 2 years of age and older with CKD and hyperphosphatemia (CKD stages 4-5 (defined by a glomerular filtration rate <30 mL/min/l .73 m²) or with CKD on dialysis). Eighty-five subjects were randomised to Velphoro (N=66) or active control calcium acetate arm (N=19) for a 10-week dose titration (Stage 1), followed by a 24-week safety extension (Stage 2). Most patients were ≥12 years of age (66%). Eighty percent of patients were CKD patients on dialysis (67% on haemodialysis and 13% on peritoneal dialysis) and 20% were CKD patients not on dialysis.
The limited difference in reduction in mean serum phosphorus level from baseline to the end of Stage 1 in the Velphoro group (N=65) was not statistically significant with -0.120 (0.081) mmol/L (95% CI: -0.282, 0.043) based on the mixed model calculations with actual data showing a mean of 2.08 mmol/L at baseline and 1.91 mmol/L at the end of Stage 1 (reduction by 0.17 mmol/L). The effect was maintained during Stage 2, although some fluctuations in mean effect over time were noticed (0.099 (0.198) mmol/L (95% CI: -0.306, 0.504)).
The percentage of subjects with serum phosphorus levels within normal ranges increased from 37% at baseline to 61% at the end of Stage 1, and was 58% at the end of Stage 2, showing the sustainable phosphorus lowering effect of sucroferric oxyhydroxide. Among subjects whose serum phosphorus was above age-related normal ranges at baseline (N=40), serum phosphorus levels showed statistically significant decrease from baseline to the end of Stage 1, with the LS mean (SE) change -0.87 (0.30) mg/dL (95% CI: -1.47, -0.27; p=0.006).
The safety profile of Velphoro in paediatric patients was generally comparable to that previously observed in adult patients.5.2 Pharmacokinetic properties
Velphoro works by binding phosphate in the gastrointestinal tract and thus the serum concentration is not relevant for its efficacy. Due to the insolubility and degradation characteristics of Velphoro, no classical pharmacokinetic studies can be carried out, e.g., determination of the distribution volume, area under the curve, mean residence time, etc.
In 2 Phase 1 studies, it was concluded that the potential for iron overload is minimal and no dose dependent effects were observed in healthy volunteers.
\*\*Absorption\*\*
The active moiety of Velphoro, pn-FeOOH, is practically insoluble and therefore not absorbed. Its degradation product, mononuclear iron species, can however be released from the surface of pn-FeOOH and be absorbed.
The absolute absorption studies in humans were not performed. Non-clinical studies in several species (rats and dogs) showed that systemic absorption was very low (≤1% of the administered dose).
The iron uptake from radiolabelled Velphoro active substance, 2,000 mg iron in 1 day was investigated in 16 CKD patients (8 pre-dialysis and 8 haemodialysis patients) and 8 healthy volunteers with low iron stores (serum ferritin <100 mcg/L). In healthy subjects, the median uptake of radiolabelled iron in the blood was estimated to be 0.43% (range 0.16 – 1.25%) on day 21, in pre-dialysis patients 0.06% (range 0.008 – 0.44%) and in haemodialysis patients 0.02% (range 0 – 0.04%). Blood levels of radiolabelled iron were very low and confined to the erythrocytes.
\*\*Distribution\*\*
The distribution studies in humans were not performed. Non-clinical studies in several species (rats and dogs) showed that pn-FeOOH is distributed from the plasma to the liver, spleen and bone marrow, and utilized by incorporation into red blood cells.
In patients, absorbed iron is expected to be also distributed to the target organs, i.e. liver, spleen and bone marrow, and utilized by incorporation into red blood cells.
\*\*Biotransformation\*\*
The active moiety of Velphoro, pn-FeOOH, is not metabolised. However, the degradation product of Velphoro, mononuclear iron species, can be released from the surface of polynuclear iron(III)-oxyhydroxide and be absorbed. Clinical studies have demonstrated that the systemic absorption of iron from Velphoro is low.
\*In vitro\* data suggest that the sucrose and starch components of the active substance can be digested to glucose and fructose, and maltose and glucose, respectively. These compounds can be absorbed in the blood.
\*\*Elimination\*\*
In animal studies with rats and dogs administered 59Fe-Velphoro active substance orally, radiolabelled iron was recovered in the faeces but not the urine.5.3 Preclinical safety data
Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.
Effects seen in the rabbit embryo-foetal development toxicity study (skeletal variations and incomplete ossificaton) are related to exaggerated pharmacology, and likely not relevant for patients. Other reproduction toxicity studies showed no adverse effects.
Carcinogenicity studies were performed in mice and rats. There was no clear evidence of a carcinogenic effect in mice. Mucosal hyperplasia, with diverticulum/cyst formation was observed in the colon and caecum of mice after 2-years treatment, but this was considered a species-specific effect with no diverticula/cysts seen in long term studies in rats or dogs. In rats, there was a slightly increased incidence of benign C-cell adenoma in the thyroid of male rats given the highest dose of sucroferric oxyhydroxide. This is thought to be most likely an adaptive response to the pharmacological effect of the medicinal product, and not clinically relevant.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
Maltodextrin
Microcrystalline cellulose
Xanthan gum
Colloidal anhydrous silica
Magnesium stearate6.2 Incompatibilities
Not applicable.6.3 Shelf life
3 years6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.6.5 Nature and contents of container
Child-resistant twin single-dose polyethylene terephthalate/aluminium/polyethylene laminate sachet. Pack size of 90 sachets.6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
\*\*Preparation and handling\*\*
Velphoro oral powder should be mixed with a small amount of soft food (such as apple sauce) or with small amount of water or non-carbonated beverage (see section 4.2). The mixture should be stirred vigorously as the powder will not dissolve completely and remain in suspension with a red-brown colour. The suspension should be administered within 30 minutes after preparation. If necessary, the suspension should be resuspended right before administration.
Enteral feeding tube
The prescribed dose of Velphoro oral powder, suspended in water as described above, may be administered via an enteral feeding tube >6 FR (French catheter scale). The tube size considered as appropriate for the intended use and age group, is 8 to 12 FR, i.e. small to medium tubes for the feeding of children and adults.
Follow the manufacturer's instructions for the feeding tube to administer the medicinal product. To ensure adequate dosing, after administration of the oral suspension, the enteral feeding tube must be flushed with water. The flush volumes to achieve a full dose recovery - for a tube with a length of 50 cm – are 6 mL (8 FR) to 10 mL (12 FR). As the medicinal product has a brownish color, a tube blockage or build-up of residues may be observed through transparent feeding tubes.
- Instruction Content
- ## Composition
Each sachet contains sucroferric oxyhydroxide corresponding to 125 mg iron.
The sucroferric oxyhydroxide contained in one sachet of oral powder is comprised of polynuclear iron (III)-oxyhydroxide (containing 125 mg iron), 187 mg sucrose and 175 mg starches (potato starch and pregelatinised maize starch).
For the full list of excipients, see section 6.1.
## Pharmaceutical Form
Oral powder in sachet.
The oral powder is red-brown.
## Clinical Particulars
4.1 Therapeutic indications
Velphoro is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD).
Velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with CKD stages 4-5 (defined by a glomerular filtration rate <30 mL/min/1.73 m²) or with CKD on dialysis.
Velphoro should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease.4.2 Posology and method of administration
\*\*Posology\*\*
\*\*\*Starting dose, dose titration and maintenance for paediatric patients 2 to <12 years of age\*\*\*
The recommended starting doses for paediatric patients in different age groups are described in Table 1.
\*\*Table 1 Recommended starting doses and dose titrations for paediatric patients 2 to <12 years of age\*\*
| | | | |
| --- | --- | --- | --- |
| \*\*Patient age (years)\*\* | \*\*Daily starting dose\*\* | \*\*Dose increases or decreases\*\* | \*\*Maximum recommended daily dose\*\* |
| ≥2 to <6 | 500 mg | 125 or 250 mg | 1,250 mg |
| ≥6 to <9 | 750 mg | 125, 250 or 375 mg | 2,500 mg |
| ≥9 to <12 | 1,000 mg | 250 or 500 mg | 3,000 mg |
Serum phosphorus levels must be monitored and the dose of sucroferric oxyhydroxide up or down titrated once per two weeks by adjusting the daily dose as indicated in Table 1 until an acceptable serum phosphorus level is reached, with regular monitoring afterwards.
For patients 6 to <12 years of age Velphoro chewable tablets may be prescribed instead of or in combination with Velphoro oral powder in case the daily dose is 1,000 mg iron (2 chewable tablets) or more.
If one or more doses are missed, the normal dose of the medicinal product should be resumed with the next meal.
\*\*\*Additional formulation and strength available\*\*\*
Velphoro is also available as chewable tablets (500 mg iron) for use in adult and paediatric patients 6 years of age and older. The choice of the formulation depends on patient's age, preference, characteristics and compliance. When transitioning between formulations, the same recommended dose should be used. Velphoro oral powder was not studied in adults. For patients 2 to <6 years of age oral powder should be administered as chewable tablet formulation is not appropriate for this age group.
\*\*\*Paediatric population <2 years of age\*\*\*
The safety and efficacy of Velphoro in children below the age of 2 years has not been established. No data are available.
\*\*\*Renal impairment\*\*\*
Velphoro is indicated for the control of serum phosphorus levels in adult CKD patients on HD or PD. There is no clinical data available in patients with earlier stages of renal impairment.
\*\*\*Hepatic impairment\*\*\*
Patients with severe hepatic impairment were excluded from participating in clinical studies with sucroferric oxyhydroxide. However, no evidence of hepatic impairment or significant alteration of hepatic enzymes were observed in the clinical studies with sucroferric oxyhydroxide. See further information in section 4.4.
\*\*Method of administration\*\*
Oral use.
In order to maximise the adsorption of dietary phosphate, the total daily dose (total number of sachets) should be divided across the main meals of the day, i.e. meals with the highest phosphate content. When total number of sachets cannot be equally divided by the number of main meals, rest of the dose should be taken with one or two main meals. The optimal way to give the total daily dose of Velphoro to individual patients should be decided based on their feeding regimens.
Before administration, Velphoro oral powder should be mixed with a small amount of soft food (such as apple sauce) or with non-carbonated beverage or water and taken with meals. Each sachet of oral powder requires minimum 5 mL of liquid for suspension, e.g. 2 sachets shall be suspended in minimum 10 mL. The amount of liquid could be increased if total daily fluid intake remains in line with dietary instructions for individual patient.
Patients should take Velphoro oral powder within 30 minutes after being suspended. Velphoro oral powder should not be heated (e.g. in a microwave) or added to heated food or liquids. The mixture should be stirred vigorously as the powder will not dissolve completely and remain in suspension with a red-brown colour. If necessary, the suspension should be resuspended right before administration.
The prescribed dose of Velphoro oral powder suspended in water as described above, may be administered via an enteral feeding tube >6 FR (French catheter scale). Follow the manufacturer's instructions for the feeding tube to administer the medicinal product. To ensure adequate dosing, after administration of the oral suspension, the enteral feeding tube must be flushed with water. See section 6.6 for further details.4.3 Contraindications
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Haemochromatosis and any other iron accumulation disorders.4.4 Special warnings and precautions for use
\*\*Peritonitis, gastric and hepatic disorders and gastrointestinal surgery\*\*
Patients with a recent history of peritonitis (within the last 3 months), significant gastric or hepatic disorders and patients with major gastrointestinal surgery have not been included in clinical studies with Velphoro. Velphoro treatment should only be used in these patients following careful assessment of benefit/risk.
\*\*Discoloured stool\*\*
Sucroferric oxyhydroxide can cause discoloured (black) stool. Discoloured (black) stool may visually mask gastrointestinal bleeding (see section 4.5).
\*\*Information about sucrose and starches (carbohydrates)\*\*
Velphoro contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product.
It may be harmful to the teeth.
Velphoro contains potato starch and pregelatinised maize starch. Patients with diabetes should take notice that one sachet of Velphoro oral powder is equivalent to approximately 0.7 g of carbohydrates (equivalent to 0.056 bread units).4.5 Interaction with other medicinal products and other forms of interaction
Velphoro is almost not absorbed from the gastrointestinal tract. Although the potential for interactions with medicinal products seems low, for concomitant treatment with medicinal products with a narrow therapeutic window, the clinical effect and adverse events should be monitored, on initiation or dose-adjustment of either Velphoro or the concomitant medicinal product, or the physician should consider measuring blood levels. When administering any medicinal product that is already known to interact with iron (like alendronate and doxycycline) or has the potential to interact with sucroferric oxyhydroxide based only on \*in vitro\* studies like levothyroxine, the medicinal product should be administered at least one hour before or two hours after Velphoro.
\*In vitro\* studies with the following active substances did not show any relevant interaction: acetylsalicylic acid, cephalexin, cinacalcet, ciprofloxacin, clopidogrel, enalapril, hydrochlorothiazide, metformin, metoprolol, nifedipine, pioglitazone and quinidine.
Interaction studies have only been performed in healthy volunteers. They have been conducted in healthy human male and female subjects with losartan, furosemide, digoxin, warfarin, and omeprazole. Concomitant administration of Velphoro did not affect the bioavailability of these medicinal products as measured by the area under the curve (AUC).
Data from clinical studies have shown that sucroferric oxyhydroxide does not affect the lipid lowering effects of HMG-CoA reductase inhibitors (e.g., atorvastatin and simvastatin). In addition, post-hoc analyses from clinical studies demonstrated no impact of Velphoro on iPTH lowering effect of oral Vitamin D analogues. Vitamin D and 1,25-dihydroxy Vitamin D levels remained unchanged.
Velphoro does not affect guaiac based (Haemoccult) or immunological based (iColo Rectal and Hexagon Obti) faecal occult blood tests.4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
There are no available clinical data from the use of sucroferric oxyhydroxide on exposed human pregnancies.
Reproductive and developmental toxicity studies in animals revealed no risk with respect to pregnancy, embryonic/foetal development, parturition or postnatal development (see section 5.3). Sucroferric oxyhydroxide should only be used by pregnant women if clearly needed following careful assessment of benefit/risk.
\*\*Breast-feeding\*\*
There are no available clinical data from the use of Velphoro in breast-feeding women. Since absorption of iron from this medicinal product is minimal (see section 5.2), excretion of iron from sucroferric oxyhydroxide in breast milk is unlikely. A decision on whether to continue breast-feeding or to continue therapy with sucroferric oxyhydroxide should be made taking into account the benefit of breast-feeding to the child and the benefit of Velphoro therapy to the mother.
\*\*Fertility\*\*
There are no data on the effect of Velphoro on fertility in humans. In animal studies, there were no adverse effects on mating performance, fertility, and litter parameters following treatment with sucroferric oxyhydroxide (see section 5.3).4.7 Effects on ability to drive and use machines
Velphoro has no or negligible influence on the ability to drive and use machines.4.8 Undesirable effects
\*\*Summary of the safety profile\*\*
The current safety profile of Velphoro is based on a total of 778 patients on haemodialysis and 57 patients on peritoneal dialysis, who received sucroferric oxyhydroxide treatment of up to 55 weeks.
In these clinical trials, approximately 43% of the patients experienced at least one adverse reaction during Velphoro treatment, and 0.36% of the adverse reactions were reported as serious. The majority of the adverse reactions reported from trials were gastrointestinal disorders, with the most frequently reported adverse reactions being diarrhoea and discoloured faeces (very common). The vast majority of these gastrointestinal disorders occurred early during treatment and abated with time with continued dosing. No dose-dependent trends were observed in the adverse reaction profile of Velphoro.
\*\*Tabulated list of adverse reactions\*\*
Adverse reactions reported from the use of Velphoro at doses from 250 mg iron/day to 3,000 mg iron/day in these patients (n=835) are listed in Table 2.
The reporting rate is classified as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100).
\*\*Table 2 Adverse reactions detected in clinical trials\*\*
| | | | |
| --- | --- | --- | --- |
| \*\*System organ class\*\* | \*\*Very common\*\* | \*\*Common\*\* | \*\*Uncommon\*\* |
| Metabolism and nutrition disorders | | | Hypercalcaemia Hypocalcaemia |
| Nervous system disorders | | | Headache |
| Respiratory, thoracic and mediastinal disorders | | | Dyspnoea |
| Gastrointestinal disorders | Diarrhoea\\* Faeces discoloured | Nausea Constipation Vomiting Dyspepsia Abdominal pain Flatulence Tooth discolouration | Abdominal distension Gastritis Abdominal discomfort Dysphagia Gastro-oesophageal reflux disease (GORD) Tongue discolouration |
| Skin and subcutaneous tissue disorders | | | Pruritus Rash |
| General disorders and administration site conditions | | Product taste abnormal | Fatigue |
\*\*Description of selected adverse reactions\*\*
\*\*\*\\*Diarrhoea\*\*\*
Diarrhoea occurred in 11.6% of patients in clinical trials. In the 55 weeks long term studies, the majority of these diarrhoea adverse reactions were transient, occurred early during treatment initiation and led to treatment discontinuation in 3.1% of the patients.
\*\*Paediatric population\*\*
In general, the safety profile of Velphoro in paediatric (2 to <18 years of age) and adult patients was comparable. The adverse reactions most frequently reported were gastrointestinal disorders including diarrhoea (very common, 16.7%), vomiting (common, 6.1%), gastritis (common, 3.0%) and discoloured faeces (common, 3.0%).
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store4.9 Overdose
Any instances of overdose of Velphoro (e.g. hypophosphataemia) should be treated by standard clinical practice.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: All other therapeutic products; drugs for treatment of hyperkalaemia and hyperphosphataemia; ATC code: V03AE05
\*\*Mechanism of action\*\*
Velphoro contains sucroferric oxyhydroxide which is comprised of polynuclear iron(III)-oxyhydroxide (pn-FeOOH), sucrose and starches. Phosphate binding takes place by ligand exchange between hydroxyl groups and/or water and the phosphate ions throughout the physiological pH range of the gastrointestinal tract.
Serum phosphorus levels are reduced as a consequence of the reduced dietary phosphate absorption.
\*\*Clinical efficacy\*\*
One phase 3 clinical study has been performed in patients with CKD on dialysis to investigate the efficacy and safety of Velphoro in this population. This study was an open-label, randomised, active-controlled (sevelamer carbonate), parallel group study for up to 55 weeks. Adult patients with hyperphosphataemia (serum phosphorus levels ≥1.94 mmol/L) were treated with sucroferric oxyhydroxide at a starting dose of 1,000 mg iron/day followed by an 8-week dose titration period. Non-inferiority to sevelamer carbonate was determined at week 12. Subjects were continued on their study medication from week 12 to week 55. From week 12 to 24, dose titrations were allowed for both tolerability and efficacy reasons. Treatment of patient sub-populations from week 24 to week 27 with maintenance dose of sucroferric oxyhydroxide (1,000 to 3,000 mg iron/day) or low dose (250 mg iron/day) of sucroferric oxyhydroxide demonstrated superiority of the maintenance dose.
In Study-05A, 1,055 patients on haemodialysis (N=968) or peritoneal dialysis (N=87) with serum phosphorus ≥1.94 mmol/L following a 2 – 4-week phosphate binder washout period, were randomised and treated with either sucroferric oxyhydroxide, at a starting dose of 1,000 mg iron/day (N=707), or active-control (sevelamer carbonate, N=348) for 24 weeks. At the end of week 24, 93 patients on haemodialysis whose serum phosphorus levels were controlled (<1.78 mmol/L) with sucroferric oxyhydroxide in the first part of the study, were re-randomised to continue treatment with either their week 24 maintenance dose (N=44 or a non-effective low dose control 250 mg iron/day, N=49) of sucroferric oxyhydroxide for a further 3 weeks.
Following completion of Study-05A, 658 patients (597 on haemodialysis and 61 on peritoneal dialysis) were treated in the 28-week extension study (Study-05B) with either sucroferric oxyhydroxide (N=391) or sevelamer carbonate (N=267) according to their original randomization.
Mean serum phosphorus levels were 2.5 mmol/L at baseline and 1.8 mmol/L at week 12 for sucroferric oxyhydroxide (reduction by 0.7 mmol/L). Corresponding levels for sevelamer carbonate at baseline were 2.4 mmol/L and 1.7 mmol/L at week 12 (reduction by 0.7 mmol/L), respectively.
The serum phosphorus reduction was maintained over 55 weeks. Serum phosphorus levels and calcium-phosphorus product levels were reduced as a consequence of the reduced dietary phosphate absorption.
The response rates, defined as the proportion of subjects achieving serum phosphorus levels within the Kidney Disease Outcomes Quality Initiative (KDOQI) recommended range were 45.3% and 59.1% at week 12 and 51.9% and 55.2% at week 52, for sucroferric oxyhydroxide and sevelamer carbonate, respectively.
The mean daily dose of Velphoro over 55 weeks of treatment was 1,650 mg iron and the mean daily dose of sevelamer carbonate was 6,960 mg.
\*\*Post-authorisation data\*\*
A prospective, non-interventional, post-authorisation safety study (VERIFIE) has been conducted, evaluating the short- and long-term (up to 36 months) safety and effectiveness of Velphoro in adult patients on haemodialysis (N=1,198) or peritoneal dialysis (N=160), who were followed in routine clinical practice for 12 to 36 months (safety analysis set, N=1,365). During the study, 45% (N=618) of these patients were concomitantly treated with phosphate binder(s) other than Velphoro.
In the safety analysis set, the most common ADRs were diarrhoea and discoloured faeces, reported by 14% (N=194) and 9% (N=128) of patients, respectively. The incidence of diarrhoea was highest in the first week and decreased with duration of use. Diarrhoea was of mild to moderate intensity in most patients and resolved in the majority of patients within 2 weeks. Discoloured (black) faeces is expected for an oral iron-based compound, and may visually mask gastrointestinal bleeding. For 4 of the 40 documented concomitant gastrointestinal bleeding events, Velphoro-related stool discolouration was reported as causing an insignificant delay in diagnosis of gastrointestinal bleeding, without affecting patient health. In the remaining cases, no delay in diagnosis of gastrointestinal bleeding has been reported.
The results from this study showed that the effectiveness of Velphoro in a real-life setting (including concomitant use of other phosphate binders in 45% of patients), was in line with that observed in the phase 3 clinical study.
\*\*Paediatric population\*\*
An open label clinical study investigated the efficacy and safety of Velphoro in paediatric patients 2 years of age and older with CKD and hyperphosphatemia (CKD stages 4-5 (defined by a glomerular filtration rate <30 mL/min/l .73 m²) or with CKD on dialysis). Eighty-five subjects were randomised to Velphoro (N=66) or active control calcium acetate arm (N=19) for a 10-week dose titration (Stage 1), followed by a 24-week safety extension (Stage 2). Most patients were ≥12 years of age (66%). Eighty percent of patients were CKD patients on dialysis (67% on haemodialysis and 13% on peritoneal dialysis) and 20% were CKD patients not on dialysis.
The limited difference in reduction in mean serum phosphorus level from baseline to the end of Stage 1 in the Velphoro group (N=65) was not statistically significant with -0.120 (0.081) mmol/L (95% CI: -0.282, 0.043) based on the mixed model calculations with actual data showing a mean of 2.08 mmol/L at baseline and 1.91 mmol/L at the end of Stage 1 (reduction by 0.17 mmol/L). The effect was maintained during Stage 2, although some fluctuations in mean effect over time were noticed (0.099 (0.198) mmol/L (95% CI: -0.306, 0.504)).
The percentage of subjects with serum phosphorus levels within normal ranges increased from 37% at baseline to 61% at the end of Stage 1, and was 58% at the end of Stage 2, showing the sustainable phosphorus lowering effect of sucroferric oxyhydroxide. Among subjects whose serum phosphorus was above age-related normal ranges at baseline (N=40), serum phosphorus levels showed statistically significant decrease from baseline to the end of Stage 1, with the LS mean (SE) change -0.87 (0.30) mg/dL (95% CI: -1.47, -0.27; p=0.006).
The safety profile of Velphoro in paediatric patients was generally comparable to that previously observed in adult patients.5.2 Pharmacokinetic properties
Velphoro works by binding phosphate in the gastrointestinal tract and thus the serum concentration is not relevant for its efficacy. Due to the insolubility and degradation characteristics of Velphoro, no classical pharmacokinetic studies can be carried out, e.g., determination of the distribution volume, area under the curve, mean residence time, etc.
In 2 Phase 1 studies, it was concluded that the potential for iron overload is minimal and no dose dependent effects were observed in healthy volunteers.
\*\*Absorption\*\*
The active moiety of Velphoro, pn-FeOOH, is practically insoluble and therefore not absorbed. Its degradation product, mononuclear iron species, can however be released from the surface of pn-FeOOH and be absorbed.
The absolute absorption studies in humans were not performed. Non-clinical studies in several species (rats and dogs) showed that systemic absorption was very low (≤1% of the administered dose).
The iron uptake from radiolabelled Velphoro active substance, 2,000 mg iron in 1 day was investigated in 16 CKD patients (8 pre-dialysis and 8 haemodialysis patients) and 8 healthy volunteers with low iron stores (serum ferritin <100 mcg/L). In healthy subjects, the median uptake of radiolabelled iron in the blood was estimated to be 0.43% (range 0.16 – 1.25%) on day 21, in pre-dialysis patients 0.06% (range 0.008 – 0.44%) and in haemodialysis patients 0.02% (range 0 – 0.04%). Blood levels of radiolabelled iron were very low and confined to the erythrocytes.
\*\*Distribution\*\*
The distribution studies in humans were not performed. Non-clinical studies in several species (rats and dogs) showed that pn-FeOOH is distributed from the plasma to the liver, spleen and bone marrow, and utilized by incorporation into red blood cells.
In patients, absorbed iron is expected to be also distributed to the target organs, i.e. liver, spleen and bone marrow, and utilized by incorporation into red blood cells.
\*\*Biotransformation\*\*
The active moiety of Velphoro, pn-FeOOH, is not metabolised. However, the degradation product of Velphoro, mononuclear iron species, can be released from the surface of polynuclear iron(III)-oxyhydroxide and be absorbed. Clinical studies have demonstrated that the systemic absorption of iron from Velphoro is low.
\*In vitro\* data suggest that the sucrose and starch components of the active substance can be digested to glucose and fructose, and maltose and glucose, respectively. These compounds can be absorbed in the blood.
\*\*Elimination\*\*
In animal studies with rats and dogs administered 59Fe-Velphoro active substance orally, radiolabelled iron was recovered in the faeces but not the urine.5.3 Preclinical safety data
Nonclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.
Effects seen in the rabbit embryo-foetal development toxicity study (skeletal variations and incomplete ossificaton) are related to exaggerated pharmacology, and likely not relevant for patients. Other reproduction toxicity studies showed no adverse effects.
Carcinogenicity studies were performed in mice and rats. There was no clear evidence of a carcinogenic effect in mice. Mucosal hyperplasia, with diverticulum/cyst formation was observed in the colon and caecum of mice after 2-years treatment, but this was considered a species-specific effect with no diverticula/cysts seen in long term studies in rats or dogs. In rats, there was a slightly increased incidence of benign C-cell adenoma in the thyroid of male rats given the highest dose of sucroferric oxyhydroxide. This is thought to be most likely an adaptive response to the pharmacological effect of the medicinal product, and not clinically relevant.
## Pharmaceutical Particulars
6.1 List of excipients
Maltodextrin
Microcrystalline cellulose
Xanthan gum
Colloidal anhydrous silica
Magnesium stearate6.2 Incompatibilities
Not applicable.6.3 Shelf life
3 years6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.6.5 Nature and contents of container
Child-resistant twin single-dose polyethylene terephthalate/aluminium/polyethylene laminate sachet. Pack size of 90 sachets.6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
\*\*Preparation and handling\*\*
Velphoro oral powder should be mixed with a small amount of soft food (such as apple sauce) or with small amount of water or non-carbonated beverage (see section 4.2). The mixture should be stirred vigorously as the powder will not dissolve completely and remain in suspension with a red-brown colour. The suspension should be administered within 30 minutes after preparation. If necessary, the suspension should be resuspended right before administration.
Enteral feeding tube
The prescribed dose of Velphoro oral powder, suspended in water as described above, may be administered via an enteral feeding tube >6 FR (French catheter scale). The tube size considered as appropriate for the intended use and age group, is 8 to 12 FR, i.e. small to medium tubes for the feeding of children and adults.
Follow the manufacturer's instructions for the feeding tube to administer the medicinal product. To ensure adequate dosing, after administration of the oral suspension, the enteral feeding tube must be flushed with water. The flush volumes to achieve a full dose recovery - for a tube with a length of 50 cm – are 6 mL (8 FR) to 10 mL (12 FR). As the medicinal product has a brownish color, a tube blockage or build-up of residues may be observed through transparent feeding tubes.
